Bernadette H. LaMonte

TL;DR: The results show that dysfunction of dynactin-mediated transport can lead to human motor neuron disease.

TL;DR: A mouse model that confirms the critical role of disrupted axonal transport in the pathogenesis of motor neuron degenerative disease is described, and dynamitin overexpression was found to disassemble dynactin, a required activator of cytoplasmic dynein, resulting in an inhibition of retrograde axonal Transport.

TL;DR: Data support a model in which a point mutation in p150Glued causes both loss of dynein/dynactin function and gain of toxic function, which together lead to motor neuron cell death.

TL;DR: Investigation of neurotracer transport from muscle to motor neuron in a transgenic mouse model of amyotrophic lateral sclerosis suggested inhibition of dynein/dynactin function may have a role in motor neuron degeneration in amyotroph lateral sclerosis.

TL;DR: Medical records of 27 horses treated with pergolide or cyproheptadine for pituitary pars intermedia dysfunction were reviewed to determine the effect of treatment on plasma ACTH, insulin, and glucose concentrations and clinical signs and there was a correlation between ACTH concentration after treatment and the duration of treatment.